- Short Communication
- Open Access
A tetravalent dengue nanoparticle stimulates antibody production in mice
© Silva et al; licensee BioMed Central Ltd. 2012
- Received: 27 June 2011
- Accepted: 22 March 2012
- Published: 22 March 2012
Dengue is a major public health problem worldwide, especially in the tropical and subtropical regions of the world. Infection with a single Dengue virus (DENV) serotype causes a mild, self-limiting febrile illness called dengue fever. However, a subset of patients experiencing secondary infection with a different serotype progresses to the severe form of the disease, dengue hemorrhagic fever/dengue shock syndrome. Currently, there are no licensed vaccines or antiviral drugs to prevent or treat dengue infections. Biodegradable nanoparticles coated with proteins represent a promising method for in vivo delivery of vaccines.
Here, we used a murine model to evaluate the IgG production after administration of inactivated DENV corresponding to all four serotypes adsorbed to bovine serum albumin nanoparticles. This formulation induced a production of anti-DENV IgG antibodies (p < 0.001). However, plaque reduction neutralization assays with the four DENV serotypes revealed that these antibodies have no neutralizing activity in the dilutions tested.
Our results show that while the nanoparticle system induces humoral responses against DENV, further investigation with different DENV antigens will be required to improve immunogenicity, epitope specicity, and functional activity to make this platform a viable option for DENV vaccines.
- inactivated Dengue vírus
- humoral response
Dengue virus (DENV) is a major public health problem worldwide, especially in the tropical and subtropical areas with around 2.5 billion people living in areas at risk . The disease is caused by a positive sense, single-stranded RNA virus that belongs to genus Flavivirus, family Flaviviridae. DENV is transmitted to humans primarily after a bite by an infected Aedes aegypti and Aedes albopictus mosquitoes. Infection with one of the DENV serotypes (DENV-1, -2, -3 and -4) causes a mild, self-limiting febrile illness called dengue fever (DF). However, after secondary infection, a small subset (~0.5%) develop the dengue hemorrhagic fever (DHF)/dengue shock syndrome (DSS), the severe form of the disease .
While vaccines could potentially prevent DENV infection or disease in humans, none are currently licensed despite decades of intensive research . To date, several approaches have been developed towards generating a tetravalent anti-DENV vaccine including live-attenuated strains, inactivated strains, subunit DNA or plasmid vaccines, and recombinant proteins . Our group has begun vaccine studies using a unique platform, the nanoparticles. Biodegradable nanoparticles are currently used as drug carriers or as adjuvants for vaccines . Polymeric nanoparticles with adsorbed or entrapped antigens represent a novel method for controlling the release of immunogens and to optimizing the immune response via selective targeting of the antigen presenting cells . In this exploratory study we evaluated the anti-DENV IgG response in mice immunized with bovine serum albumin nanoparticles adsorbed with all four serotypes of inactivated DENV.
Cell culture and virus production
C6/36 Aedes albopictus cells were grown in L-15 medium (Cultilab, Brazil) supplemented with 10% (v/v) heat-inactivated fetal bovine serum (FBS) (Cultilab, Brazil), 100 μg/mL penicillin and 100 μg/mL streptomycin at 28°C. The DENV-1, 2, 3 and 4 were isolated from dengue infected patients in Brazil and were kindly donated by Dr. Erna G. Kroon (Lab Virus, Federal University of Minas Gerais, Brazil). The propagation of each serotype of DENV was carried out in separate C6/36 cell cultures flasks. The cells were infected with DENV-1, 2, 3 or 4 at a multiplicity of infection (MOI) of 0.1 and incubated at 28°C for a week. After the development of cell syncytia, the supernatants were harvested, and titrated by standard plaque assay in LLC-MK2 cells . Heat-inactivated virus was prepared by incubating virus samples in a 55°C water bath for one hour as described previously .
Nanoparticle preparation and characterization
The nanoparticles were obtained by the addition of ethanol dropwise (ethanol:water relation 1,5:1) to an aqueous solution of bovine serum albumin (BSA) (2% w/v). The coacervates were hardened by adding 50 μL of 25% glutaraldehyde while stirring for 2 hours at room temperature. The BSA-nanoparticles were purified by three cycles of centrifugation at 13,000 g for 30 minutes to eliminate free BSA and the excess of the crosslinking agent. The supernatants were removed and the pellets resuspended in sterile PBS (final concentration of 20 mg/mL). For adsorption of inactivated viral particles to the surface of the nanoparticles (NP+DENV), 1 mL suspension of the tetravalent DENV antigenic suspension (equivalent of 1. 2 × 104 plaque forming units (PFU) for each serotype) was incubated with 1 mL of NP at 20 mg/mL. After rapid homogenization (30 seconds), the nanoparticles were purified by three successive centrifugations, each at 13,000 g for 30 minutes, 20°C. The supernatants were collected after each centrifugation and tested by Bradford assay . To determine the amount of protein adsorbed to the nanoparticles, a colorimetric assay was used and compared to the input protein and that recovered in the supernatants after centrifugation.
The presence of viral particles on the surface of NPs was demonstrated by ELISA assays using the NP+DENV as antigen. Briefly, 96-well microtiter plates were coated with NP+DENV (200 μg/well) in carbonate buffer, incubated overnight at 4°C and then washed with PBS containing 0.05% Tween-20 (PBST). Subsequently, the plates were blocked with 100 μl/well of blocking buffer (5% dry milk in PBST) for 2 h at 37°C. After three washes, 100 μl of monoclonal anti-DENV-1 (E95), anti-DENV-2 (E96), anti-DENV-3 (E51) or DENV-4 (E88) was added at 1 μg/mL [10–12] in triplicate and incubated for 1 h at 37°C. After three washes, the plates were incubated for 1 hour at 37°C with 100 μl/well of horseradish-peroxidase (HRP)-labeled anti-mouse IgG (Sigma) diluted 1:5000 in PBST. After three additional washes, the plates were incubated for 15 minutes with 0.1 ml of 0.045% H2O2 and 0.4 mg/ml of o-phenylenediaminedihydrochloride (OPD) in phosphate-citrate buffer (0.1 M citric acid, 0.2 M sodium phosphate dibasic, pH 5.0). The reaction was stopped by adding 50 μl of 2 M H2SO4. The optical densities were read at 450 nm with a microplate reader. The zeta potential of the NPs were determined with a Zetasizer 3000 HS (Malvern Instruments, UK). The surface morphology and the diameter of the formulated nanoparticles were visualized by scanning electron microscopy (Model JEOL 560).
Immunization protocol and quantification of anti-DENV and anti-BSA IgG
Six-week-old male Swiss Webster mice were used for immunizations. All mice were maintained with free access to sterile food and water, and protocols were approved by the local Animal Experimentation Ethics Committee. Mice were immunized via the subcutaneous route using 100 μg of NP (n = 15) or NP+DENV (n = 20) on days 0, 7 and 14. The mice were sacrificed 7 days after the last immunization (at day 21). Additional mice were immunized with PBS (negative control) (n = 10) or 1.2 × 104 PFU of the tetravalent DENV heat-inactivated antigenic suspension (positive control) (n = 10). Blood was collected by cardiac puncture and sera were separated for ELISA. To perform IgG quantification, 96-well microtiter plates were coated with 500 PFU/well of the inactivated DENV particles (serotypes 1 to 4) in carbonate buffer or BSA (2 μg/well). An ELISA was performed exactly as described above for quantitation of viral particles on NP, except virions were captured directly and sera from mice were used as the primary antibody. An analysis of ELISA results was performed using analysis of variance (ANOVA), and the differences between groups were evaluated with Tukey's test.
Plaque Reduction Neutralization assay (PRNA)
Briefly, heat-inactivated mouse sera were serially diluted two-fold from 1:20 to 1:320 in media and then mixed with a single DENV serotype (20 to 50 PFU/well) and incubated for 1 hour at 37°C. The mixture was inoculated onto LLC-MK2 cells in 24-well plates. Plates were incubated for 1 h before media was aspirated and replaced with 0.5 mL of 0.8% carboximethylcellulose medium (with 2% FBS). The plates are incubated at 37°C (5% CO2) for five days. At that time, cells were stained with a crystal violet solution (0.5% crystal violet, 10% ethanol and 1% paraformaldehyde) for 20 minutes, washed again, and the viral plaques were counted. The positive-control serum sample was a serum sample derived from a human patient and the antibody titers were 1:40 for DENV-1 and 1:20 for DENV-2, 3 and 4. Experiments were performed in duplicate.
The development of a dengue vaccine is considered challenging, because it must provide protective immunity against the four serotypes, without causing adverse side effects associated with incomplete immunity against a single serotype. Although the pathogenesis of the disease and protection mechanisms are not fully understood, the production of neutralizing antibodies is believed to be essential to the effectiveness of a DENV vaccine . Biodegradable nanoparticles made by BSA coated with proteins represent a promising method for in vivo delivery of protein vaccines directly to the immune system.
Thus, nanoparticles can induce anti-DENV antibodies readily, although further studies in antigen formulation will be required to induce the production of neutralizing antibodies against all four DENV serotypes.
Financial support was provided by FAPEMIG (APQ-04684-10) and CNPq (565778/2008-0).
- Gould EA, Solomon T: Pathogenic flaviviruses. Lancet. 2008, 371: 500-509.View ArticleGoogle Scholar
- Kyle JL, Harris E: Global spread and persistence of dengue. Annu Rev Microbiol. 2008, 62: 71-92.View ArticleGoogle Scholar
- Murphy BR, Whitehead SS: Immune response to dengue virus and prospects for a vaccine. Annu Rev Immunol. 2011, 29: 587-619.View ArticleGoogle Scholar
- Murrell S, Wu SC, Butler M: Review of dengue virus and the development of a vaccine. Biotechnol Adv. 2011, 29: 239-47.View ArticleGoogle Scholar
- Rice-Ficht AC, Arenas-Gamboa AM, Kahl-McDonagh MM, Ficht TA: Polymeric particles in vaccine delivery. Curr Opin Microbiol. 2010, 13: 106-112.View ArticleGoogle Scholar
- Klippstein R, Pozo D: Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies. Nanomedicine. 2010, 6: 523-529.View ArticleGoogle Scholar
- Ferreira GP, Figueiredo LB, Coelho LF, S PA, Cecilio AB, Ferreira PC, Bonjardim CA, Arantes RM, Campos MA, Kroon EG: Dengue virus 3 clinical isolates show different patterns of virulence in experimental mice infection. Microbes Infect. 2010, 12: 546-54.View ArticleGoogle Scholar
- Fink J, Gu F, Ling L, Tolfvenstam T, Olfat F, Chin KC, Aw P, George J, Kuznetsov VA, Schreiber M, Vasudevan SG, Hibberd ML: Host gene expression profiling of dengue virus infection in cell lines and patients. PLoS Negl Trop Dis. 2007, 1: e86.View ArticleGoogle Scholar
- Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976, 72: 248-54.View ArticleGoogle Scholar
- Brien JD, Austin SK, Sukupolvi-Petty S, O'Brien KM, Johnson S, Fremont DH, Diamond MS: Genotype-specific neutralization and protection by antibodies against dengue virus type 3. J Virol. 2010, 84: 10630-43.View ArticleGoogle Scholar
- Sukupolvi-Petty S, Austin SK, Engle M, Brien JD, Dowd KA, Williams KL, Rico-Hesse R, Harris E, Pierson TC, Fremont DH, Diamond MS: Structure and function analysis of therapeutic monoclonal Antibodies against dengue virus type 2. J Virol. 2010, 84: 9227-39.View ArticleGoogle Scholar
- Shrestha B, Brien JD, Sukupolvi-Petty S, Austin SK, Edeling MA, Kim T, O'Brien KM, Nelson CA, Johnson S, Fremont DH, Diamond MS: The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. PLoS Pathog. 2010, 6: e1000823-View ArticleGoogle Scholar
- Stephenson JR: Understanding dengue pathogenesis: implications for vaccine design. Bull World Health Organ. 2005, 83: 308-314.Google Scholar
- Krone B, Lenz A, Heermann KH, Seifer M, Lu XY, Gerlich WH: Interaction between hepatitis B surface proteins and monomeric human serum albumin. Hepatology. 1990, 11: 1050-1056.View ArticleGoogle Scholar
- de Alwis R, Beltramello M, Messer WB, Sukupolvi-Petty S, Wahala WM, Kraus A, Olivarez NP, Pham Q, Brien JD, Tsai WY, Wang WK, Halstead S, Kliks S, Diamond MS, Baric R, Lanzavecchia A, Sallusto F, de Silva AM: In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection. PLoS Negl Trop Dis. 2011, 5: e1188.View ArticleGoogle Scholar
- Schieffelin JS, Costin JM, Nicholson CO, Orgeron NM, Fontaine KA, Isern S, Michael SF, Robinson JE: Neutralizing and non-neutralizing monoclonal antibodies against dengue virus E protein derived from a naturally infected patient. Virol J. 2010, 4: 7-28.Google Scholar
- Beltramello M, Williams KL, Simmons CP, Macagno A, Simonelli L, Quyen NT, Sukupolvi-Petty S, Navarro-Sanchez E, Young PR, de Silva AM, Rey FA, Varani L, Whitehead SS, Diamond MS, Harris E, Lanzavecchia A, Sallusto F: The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe. 2010, 8: 271-83.View ArticleGoogle Scholar
- Dejnirattisai W, Jumnainsong A, Onsirisakul N, Fitton P, Vasanawathana S, Limpitikul W, Puttikhunt C, Edwards C, Duangchinda T, Supasa S, Chawansuntati K, Malasit P, Mongkolsapaya J, Screaton G: Cross-reacting antibodies enhance dengue virus infection in humans. Science. 2010, 328: 745-8.View ArticleGoogle Scholar
- Mukhopadhyay S, Kuhn RJ, Rossmann MG: A structural perspective of theFlavivirus life cycle. Nat Rev Microbiol. 2005, 3: 13-22.View ArticleGoogle Scholar
- Miller JL, de Wet BJ, Martinez-Pomares L, Radcliffe CM, Dwek RA, Rudd PM, Gordon S: The mannose receptor mediates dengue virus infection of macrophages. PLoS Pathog. 2008, 4: e17.View ArticleGoogle Scholar
- Lozach PY, Burleigh L, Staropoli I, Navarro-Sanchez E, Harriague J, Virelizier JL, Rey FA, Despres P, Arenzana-Seisdedos F, Amara A: Dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin (DC-SIGN)-mediated enhancement of dengue virus infection is independent of DC-SIGN internalization signals. J Biol Chem. 2005, 280: 23698-23708.View ArticleGoogle Scholar
- Wang JP, Liu P, Latz E, Golenbock DT, Finberg RW, Libraty DH: Flavivirus activation of plasmacytoid dendritic cells delineates key elements of TLR7 signaling beyond endosomal recognition. J Immunol. 2006, 177: 7114-7121.View ArticleGoogle Scholar
- Geeraedts F, Goutagny N, Hornung V, Severa M, de Haan A, Pool J, Wilschut J, Fitzgerald KA, Huckriede A: Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by Toll-like receptor signalling. PLoS Pathog. 2008, 29: e1000138.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.